article thumbnail

Marketing Partnerships with Olympic Athletes: Is it Worth the Effort for Cannabis Brands?

JD Supra Law

As the 2024 Paris Olympics draws near, many brands are eager for an opportunity to partner with Olympic athletes to enhance brand visibility and grow market share in competitive industries.

article thumbnail

MarkIt to Market® - March 2024

JD Supra Law

Welcome to the March 2024 issue of Sterne Kessler’s MarkIt to Market® newsletter. By: Sterne, Kessler, Goldstein & Fox P.L.L.C.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

"#1 Brand" claim was literally false because of apples-to-oranges comparison

43(B)log

10849 (LGS), 2024 WL 2853622 (S.D.N.Y. 4, 2024) Finding Zesty Paws’ “#1 Brand” claim literally false, the court grants a preliminary injunction despite Zesty Paws’ attempt to create a factual dispute about what a “brand” is. Nutramax and Zesty Paws are direct competitors in the pet supplement market. Nutramax Labs.,

article thumbnail

What Brands Need To Know For Marketing Compliance In 2024

IP Law 360

Testimonials, endorsements and consumer reviews have been on the Federal Trade Commission's radar for years — and since this evolving area will continue to be an enforcement priority in 2024, now is the time to ensure your house is in order, say attorneys at Crowell & Moring.

article thumbnail

Brand finance Top trademarks

Olartemoure Blog

On January 17th, 2024, Brand Finance presented its Global 500 2024 Report, highlighting the importance of trademarks as intangible assets of companies, allowing their owners to enhance their business value and potentially fuel renewed growth.

article thumbnail

How To Mitigate Political Turmoil In Influencer Marketing

IP Law 360

Ahead of the 2024 elections, brands should proactively consider tools for managing influencer campaigns, including morals clauses that can be deployed by brands for the purpose of maintaining an apolitical stance, say Matthew Savare and Bryan Sterba at Lowenstein Sandler.

article thumbnail

Balancing Innovation: India’s Views for Pharmaceuticals in the Efta Trade Deal

IIPRD

The implementation of TRIPS-Plus provisions can also readily facilitate the emergence of monopoly power for brand-name pharmaceutical companies. [v] 6, 2024). [ii] Trachtenberg, D. [vi] Henry Grabowski, Genia Long, et al, Continuing trends in US brand-name and generic drug competition, 24 Journal of Medical Economics, 908 (2021).